Biocytogen Pharmaceuticals Beijing (2315) Q1 2026 earnings summary

Executive summary

• Q1 2026 revenue rose 73.68% YoY to RMB433.1m; net profit attributable to shareholders was RMB104.0m versus a RMB13.2m loss a year earlier.

• Growth was attributed to higher pharmacology and efficacy service and animal model revenue, milestone income, and improved operating efficiency from expense management.

Financial highlights

• Operating revenue was RMB433.1m, up 73.68% YoY; operating profit was RMB105.4m versus an RMB11.7m operating loss in Q1 2025.

• Total profit was RMB105.3m and net profit attributable to shareholders was RMB104.0m, compared with losses of RMB11.7m and RMB13.2m, respectively, in Q1 2025.

• Net profit attributable to shareholders after deducting non-recurring profit or loss was RMB90.6m, versus a RMB13.1m loss in Q1 2025.

• Basic and diluted EPS were both RMB0.23, compared with RMB-0.03 in Q1 2025.

Segment performance

• Pharmacology and efficacy services and animal models were identified as the main drivers of revenue growth; no separate segment revenue figures were reported in the supplied data.